TMS Co (4891.T) Stock Price

TMS Co Price

CLOSED
138.00
​
Market closed

TMS Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co business model & stock analysis

TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization.

Frequently asked questions about TMS Co

5 analysts currently rate the TMS Co stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the TMS Co share trades at 0.78 EUR (138.00 JPY).

The revenue cannot currently be calculated for TMS Co.

The profit of TMS Co is -859.27 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of TMS Co is currently -7.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the TMS Co stock.

The P/S cannot be calculated for TMS Co currently.

The Eulerpool Quality Score for TMS Co is 3/10.

The ISIN of TMS Co is JP3544960002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of TMS Co is 4891.T. The ticker symbol is used to trade TMS Co shares on the stock exchange.

Fair ValueTerminal
126.96 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
JPY
Initial public offering
Nov 22, 2022
ISIN
JP3544960002
Cusip
J8362J103
Market capitalization
6.28 B JPYMid Cap
52-Week Range
PEG
-0.97
P/E ratio
P/Ee 2027
-5.47
P/Ee 2028
-5.72
P/Ee 2029
-4.19
P/Ee 2030
-4.08
P/S
P/Se
13.42
EV/EBIT
—
P/B Ratio
2.27
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-31.02 %
Last updated Nov 3, 2026, 9:29 AM

TMS Co Peer Group

TMS Co FIGI

4891:JP · BBG001CDXPK14891:JT · BBG01B2L8FN84891:JJ · BBG01B2L8FY64891:JE · BBG01B2L8G104891:JU · BBG01B2L8G384891:JW · BBG01B2L8G47

All fundamentals and in-depth analysis of TMS Co

Our stock analysis for TMS Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TMS Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.